Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy

Antiviral Therapy

Volumn 6, Issue 3, 2001, Pages 179-183

  Mouroux, M ^a   Descamps, D ^a   Izopet, J ^a   Yvon, A ^a   Delaugerre, C ^a   Matheron, S ^a   Coutellier, A ^a   Valantin, M A ^a   Bonmarchand, M ^a   Agut, H ^a   Massip, P ^a   Costagliola, D ^a   Katlama, C ^a   Brun Vezinet, F ^a   Calvez, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0035663666     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stavudine resistance: An update on susceptibility following prolonged therapy
2. Resistance table mutations in retroviral genes associated with drug resistance: 2000-2001 Update
3. Efficacy and tolerability of stavudine plus lamivudine in treatment- naive and treatment-experienced patients with HIV-1 infection
4. Biochemical evidence of cross-resistance to stavudine triphosphate in purified HIV-1 reverse transcriptase derived from a zidovudine-resistance isolate
5. Selection of Zidovudine resistance mutations conferring low-level resistance to Stavudine occurs at low frequency in stavudine-treated patients and in vitro during prolonged selection experiments
6. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
7. Extended HIV-1 cross-resistance to nucleoside analogues and non-nucleosidic transcriptase inhibitors following low-level escape to nucleoside analogue treatment
8. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
9. Susceptibility of HIV-1 isolates to zidovudine: Correlation between widely applicable culture test and PCR analysis
10. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes
11. Unusual mutations at codon 215 of HIV-1 reverse transcriptase in treatment-naive, HIV-1-infected persons: Prevalence, drug susceptibility and replicative fitness
12. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
13. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials
14. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
15. Selection of zidovudine resistance mutations by zidovudine or stavudine-based regimens and relationship to subsequent virological response in ACTG 370
16. Patients failing on stavudine-based therapies that have developed thymidine analogue mutations; multidrug resistance or V75T mutations have reduced phenotypic susceptibility to stavudine
17. Resistance and viral response to stavudine/lamivudine combination in zidovudine, didanosine and zalcitabine experienced patients in the ALTIS 2 ANRS trial
18. Use of neural networks to define the genetic basis of HIV-1 resitance to d4t
19. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine